Late-stage trial explores whether antibody drug can help reduce infections in facilities with a diagnosed coronavirus case

Eli Lilly & Co. has started a study exploring whether its experimental Covid-19 drug can prevent infections among vulnerable residents and staff at nursing homes and other long-term care facilities.
Indianapolis-based Lilly said Monday that it is testing its antibody-based drug in senior homes that have had a recently diagnosed case of Covid-19, putting residents and staff at high risk of exposure.
The…